RAS:RAF proximity ligation assay may predict response to KRASG12C inhibitors in NSCLC

被引：1
|
作者：
Kato, Ryoji [1 ]
Solanki, Hitendra S. [1 ]
Imbody, Denis [1 ]
Majumder, Anurima [1 ]
Stern, Yaakov [1 ]
Bridenstine, Liznair [1 ]
Johnson, Joseph [1 ]
Haura, Eric B. [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
MOLECULAR CANCER RESEARCH | 2023年 / 21卷 / 05期
关键词：
D O I：
10.1158/1557-3125.RAS23-A001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A001
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Drugging an undruggable pocket: The biochemical mechanism of covalent KRASG12C inhibitors
    Hansen, Rasmus
    Peters, Ulf
    Babbar, Anjali
    Chen, Yuching
    Feng, Jun
    Janes, Matthew R.
    Li, Liansheng
    Ren, Pingda
    Liu, Yi
    Zarrinkar, Patrick P.
    CANCER RESEARCH, 2018, 78 (13)
  • [32] Synthetic and Chromatographic Challenges and Strategies for Multigram Manufacture of KRASG12C Inhibitors
    Nikitidis, Grigorios
    Carlsson, Anna-Carin C.
    Karlsson, Staffan
    Campbell, Andrew D.
    Cook, Calum
    Dai, Kuangchu
    Emtenas, Hans
    Jonson, Anna C.
    Leek, Hanna
    Malmgren, Marcus
    Moravcik, Stefan
    Pithani, Subhash
    Tatton, Matthew R.
    Zhao, Hucheng
    Ohlen, Kristina
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2022, 26 (03) : 710 - 729
  • [33] Discovery of small-molecule inhibitors of GTP bound KRASG12C
    Gill, Adrian
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [34] The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor activity with KRASG12C inhibitors in multiple KRASG12C models
    Jameson, Nathan M.
    Kim, Gabriel
    Lee, Catherine
    Skrable, Blake
    Shea, Alexandra
    Abed, Monah
    Harismendy, Olivier
    Ma, Jianhui
    Kim, Doris
    Lackner, Mark R.
    CANCER RESEARCH, 2024, 84 (06)
  • [35] Characterising the in vivo response of lung tumors to KrasG12C inhibition
    Martins, Carla P.
    Bidar, Abdel
    Karrberg, Lillevi
    Porritt, Michelle
    Seeliger, Frank
    Whiteley, Rebecca
    Hanson, Lyndsey
    Hallengren, Liselotte
    Hardaker, Elizabeth
    Barry, Simon
    Maresca, Maresca
    Bohlooly, Mohammad
    Cosulich, Sabina
    Ross, Sarah
    CANCER RESEARCH, 2020, 80 (16)
  • [36] Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer
    Chour, Ali
    Toffart, Anne-Claire
    Berton, Elodie
    Duruisseaux, Michael
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [37] CDK12/13 inhibition antagonizes resistance to KRASG12C inhibitors.
    Stern, Yaakov E.
    Ghosh, Pompom
    Walker-Mimms, Hannah L.
    Mosior, John W.
    Imbody, Denis
    Solanki, Hitendra S.
    Monastyrskyi, Andrii
    Duckett, Derek R.
    Haura, Eric B.
    CANCER RESEARCH, 2022, 82 (23)
  • [38] The clinical dual KRASG12C inhibitor FMC-376 has demonstrated potential as both a monotherapy and in combination for the treatment of patients with KRASG12C mutation positive NSCLC
    Wang, Yan
    Roberts, Allison
    Calses, Philamer
    Neve, Richard M.
    Staunton, Jocelyn
    Webster, Kevin R.
    CANCER RESEARCH, 2024, 84 (06)
  • [39] Inhibitors of the GTPase KRASG12C in cancer: a patent review (2019-2021)
    Xu, Qifu
    Zhang, Guozhen
    Liu, Qian
    Li, Shunda
    Zhang, Yingjie
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2022, 32 (05) : 475 - 505
  • [40] Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Cardona, Andres Felipe
    Recondo, Gonzalo
    FRONTIERS IN ONCOLOGY, 2021, 11
12345